Literature DB >> 18258318

Predictors of all-cause mortality in chronic Chagas' heart disease in the current era of heart failure therapy.

Tatiana A D Theodoropoulos1, Reinaldo B Bestetti, Ana Paula Otaviano, José A Cordeiro, Vanessa C Rodrigues, Adriana C Silva.   

Abstract

BACKGROUND AND AIMS: We sought to identify predictors of all-cause mortality for Chagas' disease patients with chronic systolic heart failure because they are virtually lacking in the current era of heart failure therapy. METHODS AND
RESULTS: This study focus on 127 patients with the diagnosis of chronic systolic heart failure secondary to Chagas' cardiomyopathy. Mean follow up was 25+/-19 months. Sixty-three (50%) patients died during the study period. Cox regression analysis showed lack of B-blocking agent use (p=0.002, hazard ratio=0.30, 95% Confidence Interval 0.14 to 0.64), serum sodium levels (p=0.01, hazard ratio=0.93, 95% Confidence Interval 0.87 to 0.98), left ventricular ejection fraction (p=0.02, hazard ratio=0.96, 95% Confidence Interval 0.93 to 0.99), digoxin treatment (p=0.04, hazard ratio=8.47, 95% Confidence Interval 1.13 to 62.52) and New York Heart Association Class IV on admission (p=0.034, hazard ratio=1.92, 95% Confidence Interval 1.02 to 3.51) independent predictors of all-cause mortality.
CONCLUSION: Lack of B-blocking agent use, serum sodium levels, left ventricular ejection fraction, digoxin treatment and New York Heart Association Class IV are independent predictors of all-cause mortality for patients with chronic heart failure secondary to Chagas' cardiomyopathy in the current era of heart failure therapy.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18258318     DOI: 10.1016/j.ijcard.2007.11.057

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  18 in total

1.  Chagas Heart Failure in Patients from Latin America.

Authors:  Reinaldo B Bestetti
Journal:  Card Fail Rev       Date:  2016-11

Review 2.  Diagnosis and Management of Chagas Cardiomyopathy in the United States.

Authors:  Lillian Benck; Evan Kransdorf; Jignesh Patel
Journal:  Curr Cardiol Rep       Date:  2018-10-11       Impact factor: 2.931

Review 3.  Critical appraisal of costly therapy modalities for heart failure in a developing country.

Authors:  Diego Chemello; Livia Goldraich; Juglans Alvarez; Luis Beck-da-Silva; Nadine Clausell
Journal:  Curr Heart Fail Rep       Date:  2013-12

Review 4.  Management of Cardiovascular Disease in Patients With COVID-19 and Chronic Chagas Disease: Implications to Prevent a Scourge Still Larger.

Authors:  Reinaldo Bulgarelli Bestetti; Edimar Alcides Bocchi; Renato Bestetti; Victor Sarli Issa; Rosemary Aparecida Furlan-Daniel; Marcelo Arruda Nakazone
Journal:  Front Med (Lausanne)       Date:  2022-06-29

5.  Echocardiographic parameters and survival in Chagas heart disease with severe systolic dysfunction.

Authors:  Daniela do Carmo Rassi; Marcelo Luiz Campos Vieira; Ana Lúcia Martins Arruda; Viviane Tiemi Hotta; Rogério Gomes Furtado; Danilo Teixeira Rassi; Salvador Rassi
Journal:  Arq Bras Cardiol       Date:  2014-02-10       Impact factor: 2.000

Review 6.  Diagnosis and management of Chagas disease and cardiomyopathy.

Authors:  Antonio L Ribeiro; Maria P Nunes; Mauro M Teixeira; Manoel O C Rocha
Journal:  Nat Rev Cardiol       Date:  2012-07-31       Impact factor: 32.419

7.  Cardiac resynchronization therapy in patients with chronic Chagas cardiomyopathy: long-term follow up.

Authors:  Edgard Ferreira de Araújo; Eduardo Gregório Chamlian; Alexey Pomares Peroni; Wilson Lopes Pereira; Sylvio Matheus de Aquino Gandra; Luiz Antonio Rivetti
Journal:  Rev Bras Cir Cardiovasc       Date:  2014 Jan-Mar

8.  The effect of beta-blockade on myocardial remodelling in Chagas' cardiomyopathy.

Authors:  Walace de Souza Pimentel; Felix José Alvarez Ramires; Barbara Maria Lanni; Vera Maria Cury Salemi; Angelina Morand Bianchi Bilate; Edecio Cunha-Neto; Adriana Morgan de Oliveira; Fábio Fernandes; Charles Mady
Journal:  Clinics (Sao Paulo)       Date:  2012-09       Impact factor: 2.365

9.  Biomarkers and mortality in severe Chagas cardiomyopathy.

Authors:  Jacqueline E Sherbuk; Emi E Okamoto; Morgan A Marks; Enzo Fortuny; Eva H Clark; Gerson Galdos-Cardenas; Angel Vasquez-Villar; Antonio B Fernandez; Thomas C Crawford; Rose Q Do; Jorge Luis Flores-Franco; Rony Colanzi; Robert H Gilman; Caryn Bern
Journal:  Glob Heart       Date:  2015-09

10.  Cardiac autonomic control mechanisms in the pathogenesis of chagas' heart disease.

Authors:  Diego F Dávila; Jose H Donis; Gabriela Arata de Bellabarba; Vanesa Villarroel; Francisco Sanchez; Lisbeth Berrueta; Siham Salmen; Barbara Das Neves
Journal:  Interdiscip Perspect Infect Dis       Date:  2012-10-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.